Highlights from the 2008 Meeting of the American Society of Hematology San Francisco, CA; December 6–9, 2008
- 28 February 2009
- journal article
- Published by Elsevier BV in Clinical Leukemia
- Vol. 3 (1), 5-13
- https://doi.org/10.3816/clk.2009.n.001
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997Journal of Clinical Oncology, 2007
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndromeCancer, 2007
- Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-BBlood, 2006
- Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trialBritish Journal of Haematology, 2005
- Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBlood, 2003
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupBritish Journal of Haematology, 2001
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998